NCT00500201View on ClinicalTrials.gov

A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 24, 2007

Primary Completion Date

July 25, 2007

Study Completion Date

July 25, 2007

Conditions
Schizophrenia
Interventions
DRUG

SB- 773812 60 mg

SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.

DRUG

SB- 773812 120 mg

SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.

DRUG

Placebo

Placebo tablets will be administered orally by subjects.

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY